Educational content on VJHemOnc is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

COMy Virtual 2020 | Primary refractory young myeloma: a difficult clinical situation

Salomon Manier • 8 May 2020
COMy Virtual 2020
Multiple Myeloma Bortezomib Carfilzomib Dexamethasone Lenalidomide

Salomon Manier, MD, PhD, Lille University Hospital, Lille, France, discusses challenging cases in primary refractory young multiple myeloma. This interview was recorded via an online conference call with The Video Journal of Hematological Oncology (VJHemOnc).

More from Salomon Manier

1:54
Ongoing CAR-T trials in earlier lines of therapy in myeloma & strategies to improve efficacy
Salomon Manier • 9 Jun 2023
1:52
Impact of prior BCMA-directed therapy on the efficacy of elranatamab in R/R multiple myeloma
Salomon Manier • 9 Jun 2023
1:55
KarMMa-3 subgroup analysis: ide-cel vs standard regimens in triple-class exposed myeloma
Salomon Manier • 9 Jun 2023
3:33
Determining the optimal sequencing of bispecifics and CAR-T cells in patients with myeloma
Salomon Manier • 13 May 2023

Related Videos

1:47
Looking forward to the Miami Myeloma MRD Virtual Meeting 2024
Ola Landgren • 13 Apr 2024
2:27
The encouraging results of the LINKER-MM1 trial: safety and efficacy of linvoseltamab in R/R myeloma
Faith Davies • 9 Apr 2024
0:37
Upcoming studies investigating linvoseltamab in myeloma
Faith Davies • 9 Apr 2024
3:23
Molecular characteristics associated with increased risk of disease progression in SMM
Mark Bustoros • 27 Sep 2023
The content of VJHemOnc is intended for healthcare professionals